This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mader, J T
Right arrow Articles by Adams, K R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mader, J T
Right arrow Articles by Adams, K R

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1987 February; 31(2): 259-263

Comparative evaluation of A-56619, A-56620, and nafcillin in the treatment of experimental Staphylococcus aureus osteomyelitis.

J T Mader, L T Morrison and K R Adams

ABSTRACT

A rabbit model for Staphylococcus aureus osteomyelitis was used to compare the results of treatment with A-56619 and A-56620, two new aryl-fluoroquinolones, and nafcillin. A-56619 (15 mg/kg) and A-56620 (20 mg/kg), both used for 28 days of treatment, were injected subcutaneously every 12 h, and nafcillin (40 mg/kg) was injected every 6 h. After treatment, S. aureus was found on bone marrow cultures from 19 of 20 control rabbits, 6 of 20 treated with A-56619, 14 of 20 treated with A-56620, and 8 of 20 treated with nafcillin. Drug concentrations in serum and uninfected and infected bone were measured 1 h after A-56619 and A-56620 injection and 30 min after nafcillin injection in a group of rabbits that had been infected for 3 to 4 weeks. The concentrations in infected bone were similar for all three drugs and were significantly higher than in uninfected bone. The results of this study showed that A-56619 had a high rate of eradication of S. aureus from infected bone and compared favorably to nafcillin.


Antimicrob Agents Chemother. 1987 February; 31(2): 259-263




This article has been cited by other articles:

  • Brady, R. A., Leid, J. G., Camper, A. K., Costerton, J. W., Shirtliff, M. E. (2006). Identification of Staphylococcus aureus Proteins Recognized by the Antibody-Mediated Immune Response to a Biofilm Infection.. Infect. Immun. 74: 3415-3426 [Abstract] [Full Text]  
  • Shirtliff, M. E., Calhoun, J. H., Mader, J. T. (2002). Gatifloxacin Efficacy in Treatment of Experimental Methicillin-Sensitive Staphylococcus aureus-Induced Osteomyelitis in Rabbits. Antimicrob. Agents Chemother. 46: 231-233 [Abstract] [Full Text]  
  • Shirtliff, M. E., Calhoun, J. H., Mader, J. T. (2001). Comparative evaluation of oral levofloxacin and parenteral nafcillin in the treatment of experimental methicillin-susceptible Staphylococcus aureus osteomyelitis in rabbits. J Antimicrob Chemother 48: 253-258 [Abstract] [Full Text]